A model for predicting the overall survival of gastroenteropancreatic neuroendocrine neoplasms after surgery

References

• Dasari A, Shen C, Halperin D, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3(10):1335–1342.
   PubMed Web of Science ®Google Scholar
• Huguet I, Grossman AB, O'Toole D. Changes in the epidemiology of neuroendocrine tumours. Neuroendocrinology. 2017;104(2):105–111.
   PubMed Web of Science ®Google Scholar
• Fraenkel M, Kim M, Faggiano A, Knowledge NETwork, et al. Incidence of gastroenteropancreatic neuroendocrine tumours: a systematic review of the literature. Endocr Relat Cancer. 2014;21(3):R153–163.
   PubMed Web of Science ®Google Scholar
• Cao Y, Ma Y, Yu J, et al. Favorable response to immunotherapy in a pancreatic neuroendocrine tumor with temozolomide-induced high tumor mutational burden. Cancer Communications (London, England). 2020;40(12):746–751.
   PubMed Web of Science ®Google Scholar
• Pavel M, Öberg K, Falconi M, et al. Gastroenteropancreatic neuroendocrine neoplasms: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(7):844–860.
   PubMed Web of Science ®Google Scholar
• Aristizabal Prada ET, Auernhammer CJ. Targeted therapy of gastroenteropancreatic neuroendocrine tumours: preclinical strategies and future targets. Endocr Connect. 2018;7(1):R1–r25.
   PubMed Web of Science ®Google Scholar
• Klöppel G, La Rosa S. Ki67 labeling index: assessment and prognostic role in gastroenteropancreatic neuroendocrine neoplasms. Virchows Arch. 2018;472(3):341–349.
   PubMed Web of Science ®Google Scholar
• Chai SM, Brown IS, Kumarasinghe MP. Gastroenteropancreatic neuroendocrine neoplasms: selected pathology review and molecular updates. Histopathology. 2018;72(1):153–167.
   PubMed Web of Science ®Google Scholar
• Bertani E, Ravizza D, Milione M, et al. Neuroendocrine neoplasms of rectum: a management update. Cancer Treat Rev. 2018;66:45–55.
   PubMed Web of Science ®Google Scholar
• Amin MB, Greene FL, Edge S. e. AJCC cancer staging manual [M]. 8th ed. New York: Springer. 2016.
   Google Scholar
• Rindi G, Klöppel G, Couvelard A, et al. TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 2007;451(4):757–762.
   PubMed Web of Science ®Google Scholar
• Nagtegaal ID, Odze RD, Klimstra D, WHO Classification of Tumours Editorial Board, et al. The 2019 WHO classification of tumours of the digestive system. Histopathology. 2020;76(2):182–188.
   PubMed Web of Science ®Google Scholar
• Park SY. Nomogram: an analogue tool to deliver digital knowledge. J Thorac Cardiovasc Surg. 2018;155(4):1793.
   PubMed Web of Science ®Google Scholar
• Wang S, Yang L, Ci B, et al. Development and validation of a nomogram prognostic model for SCLC patients. J Thora Oncol. 2018;13(9):1338–1348.
   PubMed Web of Science ®Google Scholar
• Wang Y, Du L, Yang X, et al. A nomogram combining long non-coding RNA expression profiles and clinical factors predicts survival in patients with bladder cancer. Aging. 2020;12(3):2857–2879.
   PubMedGoogle Scholar
• Su J, Miao LF, Ye XH, et al. Development of prognostic signature and nomogram for patients with breast cancer. Medicine. 2019;98(11):e14617.
   PubMed Web of Science ®Google Scholar
• National Cancer Institute (NCI). Surveillance E, and End Results Program. SEER Fact Sheets: SEER Program Overview. [cited 2020 Mar 17]. Available from: https://seer.cancer.gov/about/overview.html.
   Google Scholar
• Man D, Wu J, Shen Z, et al. Prognosis of patients with neuroendocrine tumor: a SEER database analysis. Cancer Manag Res. 2018;10:5629–5638.
   PubMed Web of Science ®Google Scholar
• Sorbye H, Baudin E, Perren A. The problem of High-Grade gastroenteropancreatic neuroendocrine neoplasms: Well-Differentiated neuroendocrine tumors, neuroendocrine carcinomas, and Beyond. Endocrinol Metab Clin North Am. 2018;47(3):683–698.
   PubMed Web of Science ®Google Scholar
• Huang PY, Tsai KL, Liang CM, et al. Prognostic factors of patients with gastroenteropancreatic neuroendocrine neoplasms. Kaohsiung J Med Sci. 2018;34(11):650–656.
   PubMed Web of Science ®Google Scholar
• Doll KM, Rademaker A, Sosa JA. Practical guide to surgical data sets: Surveillance, epidemiology, and end results (SEER) database. JAMA Surg. 2018;153(6):588–589.
   PubMed Web of Science ®Google Scholar
• Iasonos A, Schrag D, Raj GV, et al. How to build and interpret a nomogram for cancer prognosis. J Clin Oncol. 2008;26(8):1364–1370.
   PubMed Web of Science ®Google Scholar
• Jr. FEH rms: Regression Modeling Strategies. R package version 6.0-0. 2020. Available from: https://CRAN.R-project.org/package=rms.
   Google Scholar
• A Package for Survival Analysis in R_. R package version 3.2-3. 2020. Available from: https://CRAN.R-project.org/package=survival.
   Google Scholar
• Shi H, Jiang C, Zhang Q, et al. Clinicopathological heterogeneity between primary and metastatic sites of gastroenteropancreatic neuroendocrine neoplasm. Diagn Pathol. 2020;15(1):108.
   PubMed Web of Science ®Google Scholar
• Xie S, Li L, Wang X, et al. Development and validation of a nomogram for predicting the overall survival of patients with gastroenteropancreatic neuroendocrine neoplasms. Medicine. 2021;100(2):e24223.
   PubMed Web of Science ®Google Scholar
• Milione M, Maisonneuve P, Spada F, et al. The clinicopathologic heterogeneity of grade 3 gastroenteropancreatic neuroendocrine neoplasms: morphological differentiation and proliferation identify different prognostic categories. Neuroendocrinology. 2017;104(1):85–93.
   PubMed Web of Science ®Google Scholar
• Fazio N, Milione M. Heterogeneity of grade 3 gastroenteropancreatic neuroendocrine carcinomas: New insights and treatment implications. Cancer Treat Rev. 2016;50:61–67.
   PubMed Web of Science ®Google Scholar
• Nuñez-Valdovinos B, Carmona-Bayonas A, Jimenez-Fonseca P, et al. Neuroendocrine tumor heterogeneity adds uncertainty to the world health organization 2010 classification: Real-World data from the spanish tumor registry (R-GETNE). The Oncologist. 2018;23(4):422–432.
   PubMed Web of Science ®Google Scholar
• Carmona-Bayonas A, Jiménez-Fonseca P, Lamarca Á, et al. Prediction of progression-free survival in patients with advanced, well-differentiated, neuroendocrine tumors being treated with a somatostatin analog: the GETNE-TRASGU study. J Clin Oncol. 2019;37(28):2571–2580.
   PubMed Web of Science ®Google Scholar
• Strosberg JR, Weber JM, Feldman M, et al. Prognostic validity of the american joint committee on cancer staging classification for midgut neuroendocrine tumors. J Clin Oncol. 2013;31(4):420–425.
   PubMed Web of Science ®Google Scholar
• Rindi G, Falconi M, Klersy C, et al. TNM staging of neoplasms of the endocrine pancreas: results from a large international cohort study. J Natl Cancer Inst. 2012;104(10):764–777.
   PubMedGoogle Scholar
• Strosberg JR, Cheema A, Weber JM, et al. Relapse-free survival in patients with nonmetastatic, surgically resected pancreatic neuroendocrine tumors: an analysis of the AJCC and ENETS staging classifications. Ann Surg. 2012;256(2):321–325.
   PubMed Web of Science ®Google Scholar
• Jann H, Roll S, Couvelard A, et al. Neuroendocrine tumors of midgut and hindgut origin: tumor-node-metastasis classification determines clinical outcome. Cancer. 2011;117(15):3332–3341.
   PubMed Web of Science ®Google Scholar
• Jie C, Man L. Advances in drug treatment of gastroenteropancreatic neuroendocrine tumors. Chin J Dig. 2019;8:208–512.
   Google Scholar
• Yao JC, Pavel M, Lombard-Bohas C, et al. Everolimus for the treatment of advanced pancreatic neuroendocrine tumors: Overall survival and circulating biomarkers from the randomized, phase III RADIANT-3 study. J Clin Oncol. 2016;34(32):3906–3913.
   PubMed Web of Science ®Google Scholar
• Yao JC, Fazio N, Singh S, et al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet (London, England). 2016;387(10022):968–977.
   PubMed Web of Science ®Google Scholar
• Faivre S, Niccoli P, Castellano D, et al. Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized study. Ann Oncol. 2017;28(2):339–343.
   PubMed Web of Science ®Google Scholar
• Stueven AK, Kayser A, Wetz C, et al. Somatostatin analogues in the treatment of neuroendocrine tumors: past, present and future. IJMS. 2019;20(12):3049.
   Web of Science ®Google Scholar